Medical Devices Market: as chronic disease proliferation and minimally invasive procedure volumes outpace what healthcare system capacity expansion can absorb at current reimbursement trajectories, large conglomerates are simultaneously divesting slower-growth divisions and acquiring next-generation platforms in the fastest-growing therapeutic categories, so portfolio reshaping is compounding capital concentration in cardiovascular and structural heart faster than the underlying disease burden alone would predict.

The global medical devices market size was USD 635.20 Billion in 2025 and is expected to register a revenue CAGR of 6.5% during the forecast period.Market revenue growth is driven by factors such as the expanding global burden of chronic non-communicable diseases sustaining capital equipment and consumable demand, accelerating minimally invasive procedure volumes displacing open surgical approaches, and an ageing population sustaining sustained replacement-cycle and new-patient device demand.The first driving factor is the expanding global burden of chronic non-communicable diseases. The International Diabetes Federation reported that 589 million adults aged 20 to 79 were living with diabetes in 2024, representing 11.1% of the global adult population and a 9.7% increase over the 2021 figure.The second driving factor is the rising cardiovascular disease burden sustaining procedural device demand. The Global Burden of Cardiovascular Diseases and Risks 2023 Collaboration estimated that cardiovascular diseases accounted for 437 million disability-adjusted life years globally in 2023, a 1.4-fold increase from 1990.The third driving factor is sustained reimbursement support for expanding device indications, with CMS confirming that transcatheter aortic valve replacement reimbursement rates support continued adoption in lower-surgical-risk patient populations beyond the original high-risk approval cohorts.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a large medtech conglomerate's portfolio reshaping, divesting slower-growth divisions while acquiring platforms in the fastest-growing therapeutic categories, concentrates capital and commercial focus on cardiovascular and structural heart faster than organic disease-burden growth alone would generate.Once a conglomerate divests a lower-growth division, the freed capital and management attention flow directly into acquiring platform technology in adjacent high-growth categories the company already sells into, so revenue concentration compounds in the fastest-growing categories without requiring the acquirer to build an entirely new commercial relationship or sales channel from scratch.As a result, demand and revenue share are concentrating around device categories where the largest conglomerates are simultaneously divesting and reinvesting, that hold the deepest capital reallocation momentum, and the forecast tilts toward cardiovascular and structural heart device categories rather than the slower-growth divisions being divested.For instance, in January 2026, Boston Scientific announced a definitive agreement to acquire Penumbra for USD 14.50 Billion, expanding its neurovascular and interventional thrombectomy portfolio, one of several 2025-2026 mega-deals that together brought disclosed medtech M&A value to over USD 80 Billion in 2025 alone, according to Bain & Company, as large conglomerates including BD, Medtronic, and J&J simultaneously executed significant divestitures to concentrate capital on faster-growing segments.These are some of the key factors driving revenue growth of the market.

Because value analysis committees at major integrated delivery networks have extended capital equipment purchase cycles and renegotiated consumable pricing frameworks, this compresses average selling prices for high-volume single-use devices and commodity surgical instruments by 3 to 6% per annum.

Regulatory pathway extensions are a second constraint, since EU MDR's full transition from the Medical Device Directive has delayed CE Mark renewal of established device categories, with a significant proportion of devices holding valid legacy CE Marks not yet securing MDR-compliant notified body review due to capacity constraints.

Supply chain cost normalisation is a third constraint, as Iran-US sanctions maintain elevated freight and logistics costs on specialty silicone polymer precursors and rare earth elements transiting through Strait of Hormuz shipping corridors.

These factors substantially limit medical devices market growth over the forecast period.

The clearest driver of demand is the structural increase in device content per procedure as minimally invasive techniques replace open surgical approaches. A minimally invasive procedure only displaces its open surgical equivalent at scale if it delivers genuinely better patient outcomes at comparable or lower total procedural cost, and reduced patient recovery time, hospital length of stay, and post-procedural complication rates have made that case decisively across cardiovascular and orthopaedic indications. A study drawing on CMS Medicare Part B data confirmed that primary total knee arthroplasty volume exceeded one million adjusted procedures in the United States in 2022 and is projected to grow at 5.9% annually through 2040, providing a durable demand anchor for orthopaedic implant and consumable device categories. In January 2025, Medtronic announced its board-approved strategic decision to separate its Diabetes operating unit into a new standalone publicly listed company, a portfolio action reflecting the scale and commercial maturity of diabetes care devices as a standalone market with addressable patient populations exceeding 500 million globally. The effect on the market is that device content per procedure is rising structurally across cardiovascular and orthopaedic categories, sustaining consumable and capital equipment revenue growth beyond what raw procedure volume growth alone would generate. These are some of the key factors driving revenue growth of the market.

The second driver is the historic acceleration of medtech M&A activity concentrating capital in the fastest-growing device categories. A conglomerate only reallocates capital toward a new therapeutic category at scale if it can acquire established commercial and clinical infrastructure rather than building it organically, and the 2025-2026 wave of large medtech acquisitions has done exactly that, concentrating deal value in cardiovascular, neurovascular, and structural heart platforms specifically. Disclosed medtech M&A deal value exceeded USD 80 Billion in 2025, according to Bain & Company, surpassing the previous three years combined, with the first quarter of 2026 alone exceeding USD 40 Billion in announced transactions. In May 2026, Stryker completed its acquisition of Amplitude Vascular Systems for an intravascular lithotripsy platform, entering a category that has already attracted Johnson & Johnson's USD 13.10 Billion Shockwave Medical acquisition, Boston Scientific, and Abbott, while Abbott closed its USD 21 Billion acquisition of Exact Sciences in March 2026 and Medtronic agreed to acquire SPR Therapeutics for approximately USD 650 Million in May 2026 to expand its neuromodulation portfolio. The effect on the market is that cardiovascular, neurovascular, and structural heart device categories are capturing a disproportionate share of both organic growth and M&A-driven capital reallocation simultaneously. These are some of the key factors driving revenue growth of the market.

“Disclosed medtech M&A deal value exceeded USD 80 Billion in 2025, surpassing the previous three years combined, with intravascular lithotripsy alone attracting Johnson & Johnson, Boston Scientific, Abbott, and now Stryker into direct competition for the same next-generation cardiovascular platform.”

The third driver is the steady expansion of reimbursement-supported clinical indications beyond the narrow high-risk populations in which advanced devices originally received approval. A device category only sustains long-term revenue growth beyond its initial approval cohort if reimbursement policy keeps pace with expanding clinical evidence, and CMS's 2024 Physician Fee Schedule final rule maintaining transcatheter aortic valve replacement reimbursement rates at levels supporting continued adoption in lower-surgical-risk populations does exactly that. The AdvaMed Medtech Industry Report documented that the US medical device industry employs approximately 425,000 people directly and contributes an estimated USD 200 Billion annually to economic activity, reflecting the innovation ecosystem sustaining new product introduction rates across device categories. BD's agreement to sell its biosciences and diagnostics solutions unit to Waters for USD 17.50 Billion, expected to close in the coming months, reflects the same portfolio-reshaping logic driving conglomerates toward the categories where reimbursement-supported indication expansion offers the clearest growth runway. The effect on the market is that device categories with the clearest reimbursement expansion trajectory, structural heart chief among them, are compounding market share gains well beyond their original approved patient population. These are some of the key factors driving revenue growth of the market.

However, the medical devices market faces severe adoption constraints from hospital procurement cost-containment pressure, EU MDR regulatory pathway extensions, and supply chain cost normalisation.

Because value analysis committees at major integrated delivery networks in the United States and Western Europe have extended capital equipment purchase cycles and renegotiated consumable pricing frameworks in response to healthcare system budget pressure, this compresses average selling prices for high-volume single-use devices and commodity surgical instruments by 3 to 6% per annum.

Regulatory pathway extensions compound this, since EU MDR's full transition from the Medical Device Directive, completed in May 2024, has delayed CE Mark renewal of established device categories including orthopaedic implants and diagnostic imaging components, with the European Commission reporting that a significant proportion of devices holding valid legacy CE Marks had not yet secured MDR-compliant notified body review due to capacity constraints.

Supply chain cost normalisation is the third constraint, since Iran-US sanctions maintain elevated freight and logistics costs on specialty silicone polymer precursors and rare earth elements used in medical imaging magnet assemblies transiting through Strait of Hormuz shipping corridors, sustaining input cost headwinds at manufacturing facilities in Western Europe and Asia.

These factors substantially limit medical devices market growth over the forecast period.

Based on product type, the global medical devices market is segmented into cardiovascular, diagnostic imaging, orthopaedic, endoscopy, diabetes care, and surgical instrument devices. Cardiovascular devices hold the largest revenue share, because the scale of global cardiovascular disease burden combined with the intensity of current M&A-driven capital investment concentrates both organic and inorganic growth in this single category more than any other. Diagnostic imaging devices are expected to register a rapid revenue growth rate, driven by AI-enabled imaging device authorizations, with the FDA authorizing over 1,300 AI/ML-enabled devices to date and 258 cleared in 2025 alone, a record year.

Based on application, the global medical devices market is segmented into cardiology, orthopaedics and spine, diagnostic imaging, diabetes management, and general surgery. Diabetes management holds a significantly large application revenue share, reflecting the scale of the global diabetic patient population and the recurring consumable revenue model of continuous glucose monitoring and insulin delivery systems. Cardiology is expected to register the fastest revenue growth rate, driven by the concentration of 2025-2026 M&A activity in structural heart and intravascular lithotripsy platforms at Boston Scientific, Stryker, Abbott, and Medtronic.

Based on regional analysis, the medical devices market in North America accounted for largest revenue share in 2025. The United States leads because CMS reimbursement policy directly shapes device adoption at national scale, and because the country hosts the headquarters of Medtronic, Johnson & Johnson MedTech, Abbott, and Stryker, four of the five largest medtech companies globally by device revenue. The AdvaMed Medtech Industry Report confirmed the US medical device industry employs approximately 425,000 people directly and contributes an estimated USD 200 Billion annually to economic activity. The concentration of the largest medtech conglomerates in the United States also means new device categories and reimbursement pathways are often established domestically before being extended to other regions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and Italy represent the four largest national markets, with Siemens Healthineers and Philips anchoring the region's diagnostic imaging device manufacturing base. The EU MDR's full transition from the Medical Device Directive has increased pre-market and renewal compliance burden substantially, but notified body capacity constraints continue to create submission timeline bottlenecks that outsourced testing and regulatory capacity alone cannot resolve. The result is steady rather than rapid growth, shaped more by notified body throughput constraints than by underlying clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period, driven by China, Japan, India, and South Korea's expanding hospital infrastructure investment and rising chronic disease prevalence. China's rapidly expanding hospital network and India's growing device manufacturing and procurement scale are the region's two largest growth contributors, while Japan's advanced imaging and cardiovascular device adoption sustains premium device demand. This leaves more room for growth than in the more mature North American and European device markets, where manufacturer-institution relationships are already largely established.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets, with device access concentrated at private hospital networks in São Paulo and Mexico City. Iran-US sanctions continue to disrupt freight and import costs for the specialty silicone polymer precursors and rare earth elements used in medical imaging magnet assemblies that Latin American device manufacturers and distributors depend on, with cargo rerouting around the Strait of Hormuz corridor raising landed input costs and slowing device manufacturing and distribution capacity expansion beyond the region's main centres through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC commercial markets, with the Saudi Vision 2030 healthcare investment programme driving new demand for advanced device procurement. The UAE is the most established market on the continent for advanced medical device adoption, while the Gulf states more broadly are still building institutional procurement and regulatory infrastructure largely from scratch.